@article{oai:nagoya.repo.nii.ac.jp:00028368,
 author = {Kawashima, Nozomu and Iida, Minako and Suzuki, Ritsuro and Fukuda, Takahiro and Atsuta, Yoshiko and Hashii, Yoshiko and Inoue, Masami and Kobayashi, Masao and Yabe, Hiromasa and Okada, Keiko and Adachi, Souichi and Yuza, Yuki and Kawa, Keisei and Kato, Koji},
 issue = {4},
 journal = {International Journal of Hematology},
 month = {Apr},
 note = {We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0–15 years; 89 males and 52 females) during 1995–2011. Donors were primarily unrelated and mismatched related. In the GVHD prophylaxis group, 29% and 8.6% of patients developed grade II–IV and III–IV GVHD, respectively. Of the 32 evaluable patients, 16% developed chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment group, 61% had decreased grade. In the chronic GVHD treatment group, 36% had improved symptoms. Combined immunosuppressant was reduced or discontinued in 61% patients. Major adverse events (AEs) were neutropenia (4.3%), infection (3.5%), thrombocytopenia (2.1%), myelosuppression (2.1%), and diarrhea (1.4%). MMF dosage was reduced in two children due to grade ≥ 3 AEs; two children died from infection. MMF thus may be well tolerated in children, and may be an effective option for prophylaxis and treatment of acute and chronic GVHD., ファイル公開：2020/04/01},
 pages = {491--498},
 title = {Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan},
 volume = {109},
 year = {2019}
}